SequelSEC

AtriCure, Inc. ATRC

Surgical & Medical Instruments & Apparatus · CIK 0001323885 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$153.60M
Fiscal year ended 2026-06-30
Operating income
$9.66M
Fiscal year ended 2026-06-30
Free cash flow
$18.43M
Fiscal year ended 2026-06-30

AtriCure, Inc. (ATRC) reported revenue of $153.60M and net income of $8.96M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from AtriCure, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

AtriCure, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$153.60M$141.25M$140.50M$134.27M$136.14M$123.62M$124.28M$115.91M$116.27M$108.85M
Cost of revenue$34.98M$31.94M$35.16M$32.94M$34.66M$30.99M$31.66M$29.12M$29.42M$27.58M
Gross profit$118.63M$109.31M$105.34M$101.33M$101.48M$92.63M$92.62M$86.79M$86.84M$81.27M
Operating income$9.66M$526.00K$2.49M$208.00K-$6.19M-$5.95M-$14.52M-$7.40M-$7.17M-$10.92M
Net income$8.96M$108.00K$1.76M-$267.00K-$6.19M-$6.75M-$15.57M-$7.85M-$8.01M-$13.27M
Research & development$26.40M$24.24M$24.50M$22.89M$29.28M$22.53M$34.96M$20.96M$20.42M$19.84M
Weighted-average diluted sharesshares 48.87Mshares 49.05MUnavailableshares 47.92Mshares 47.72Mshares 47.39MUnavailableshares 47.10Mshares 46.91Mshares 46.72M
Pretax income$9.43M$394.00K$2.36M-$86.00K-$5.93M-$6.51M-$15.30M-$7.53M-$7.76M-$13.09M
Income tax expense$471.00K$286.00K$604.00K$181.00K$261.00K$239.00K$266.00K$322.00K$253.00K$183.00K
Diluted EPS$0.18$0.00Unavailable$-0.01$-0.13$-0.14Unavailable$-0.17$-0.17$-0.28
Selling, general & administrative$82.56M$84.55M$78.34M$78.23M$78.39M$76.05M$72.18M$73.24M$73.60M$72.34M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

AtriCure, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$167.79M$146.16M$167.43M$147.86M$117.80M$99.88M$122.72M$130.34M$106.04M$64.97M
Total assets$676.64M$643.99M$654.18M$635.44M$608.85M$591.63M$609.33M$615.07M$597.27M$591.63M
Current assets$345.53M$313.69M$322.52M$301.11M$271.26M$251.48M$267.83M$269.29M$252.85M$245.22M
Total liabilities$160.21M$152.30M$162.24M$158.94M$144.36M$137.01M$148.36M$150.05M$135.19M$135.32M
Current liabilities$81.92M$73.19M$81.52M$77.84M$68.84M$61.22M$73.42M$74.43M$61.22M$61.25M
Total equity incl. NCI$516.43M$491.69M$491.94M$476.51M$464.49M$454.62M$460.97M$465.02M$462.08M$456.31M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$83.92M$81.14M$78.49M$78.95M$76.34M$74.91M$75.34M$76.55M$73.65M$71.94M
Accounts receivable$79.98M$71.31M$66.65M$62.98M$66.00M$63.32M$60.34M$54.91M$55.57M$55.32M
Goodwill$234.78M$234.78M$234.78M$234.78M$234.78M$234.78M$234.78M$234.78M$234.78M$234.78M
Long-term debt$61.00M$61.00M$61.86M$61.86M$61.86M$61.86M$61.86M$61.86M$61.86M$61.86M
Accounts payable$35.85M$30.56M$25.31M$25.47M$25.68M$25.18M$25.03M$31.74M$26.67M$28.99M

Cash flow

AtriCure, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$22.19M-$4.00M$20.03M$26.72M$21.62M-$11.03M$5.84M$20.00M$7.38M-$21.02M
Capital expenditures$3.77M$3.85M$1.60M$2.60M$2.66M$2.18M$2.69M$3.61M$2.38M$2.77M
Investing cash flow-$3.77M-$3.85M-$2.60M-$2.60M-$7.66M-$1.68M-$14.69M$4.39M$30.89M$9.64M
Financing cash flow$3.26M-$13.26M$2.10M$5.98M$3.42M-$10.32M$1.74M-$333.00K$2.85M-$7.86M
Net change in cash$21.62M-$21.26M$19.56M$30.07M$17.91M-$22.84M-$7.61M$24.30M$41.07M-$19.34M
Stock-based compensation$12.31M$11.27M$11.26M$12.42M$11.37M$9.63M$10.38M$10.36M$10.39M$9.26M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

AtriCure, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$18.43M-$7.85M$18.42M$24.11M$18.96M-$13.21M$3.14M$16.40M$5.00M-$23.79M
Gross margin77.2%77.4%75.0%75.5%74.5%74.9%74.5%74.9%74.7%74.7%
Operating margin6.3%0.4%1.8%0.2%-4.5%-4.8%-11.7%-6.4%-6.2%-10.0%
FCF margin12.0%-5.6%13.1%18.0%13.9%-10.7%2.5%14.1%4.3%-21.9%
SBC / revenue8.0%8.0%8.0%9.3%8.4%7.8%8.4%8.9%8.9%8.5%
Current ratio4.22x4.29x3.96x3.87x3.94x4.11x3.65x3.62x4.13x4.00x
Revenue YoY growth12.8%14.3%13.1%15.8%17.1%13.6%16.6%17.9%15.2%16.4%
Net margin5.8%0.1%1.2%-0.2%-4.5%-5.5%-12.5%-6.8%-6.9%-12.2%
R&D / revenue17.2%17.2%17.4%17.0%21.5%18.2%28.1%18.1%17.6%18.2%
CapEx / revenue2.5%2.7%1.1%1.9%2.0%1.8%2.2%3.1%2.1%2.5%
Long-term debt / equity0.12xUnavailable0.13x0.13xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate5.0%72.6%25.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATRC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-27View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.